Palvella Therapeutics Inc (PI6)
XFRA 
NASDAQ (CM) Primary XFRA Summary
PI6 Chart
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?
Pieris Pharmaceuticals (NASDAQ: PIRS ) stock is rocketing higher on Wednesday after announcing a merger agreement with Palvella Therapeutics. Pieris Pharmaceuticals and Palvella Therapeutics will enact an all-stock transfer for this merger.
Palvella Therapeutics Inc (PI6) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Palvella Therapeutics Inc ever had a stock split?
Palvella Therapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | Stephen S. Yoder CEO | XFRA Exchange | US7207951036 ISIN |
| US Country | 46 Employees | - Last Dividend | 23 Apr 2024 Last Split | 13 Apr 2015 IPO Date |
Overview
Pieris Pharmaceuticals, Inc. is an innovative biotechnology firm established in 2001 with a head office located in Boston, Massachusetts. The company is engaged in the discovery and development of advanced biotechnological applications with a particular emphasis on immuno-oncology (IO). Through its strategic partnerships and cutting-edge research, Pieris Pharmaceuticals aims to catalyze advancements in the treatment of cancer and other serious diseases by harnessing the power of its proprietary 4-1BB bispecifics programs.
Products and Services
- S095012 (PRS-344)
A groundbreaking bispecific Mabcalin compound co-developed with Les Laboratoires Servier and Institut de Recherches Internationales Servier, S095012 (PRS-344) uniquely targets PD-L1 and 4-1BB. This dual-targeting mechanism is designed to enhance the immune system's ability to fight cancer. Currently under phase 1 clinical studies, the compound promises to be a significant advancement in IO therapies.
- SGN-BB228 (PRS-346)
In collaboration with Pfizer Inc., SGN-BB228 (PRS-346) is a novel CD228 x 4-1BB bispecific antibody-Anticalin compound. By targeting CD228 and 4-1BB, it leverages a unique pathway to stimulate an immune response against cancer cells. This product is part of Pieris Pharmaceuticals' effort to develop more effective cancer treatments and is also in phase 1 of clinical research.
- BOS-342 (PRS-342)
A collaboration with Boston Pharmaceuticals has given rise to BOS-342 (PRS-342), a bispecific Mabcalin compound targeting GPC3 and 4-1BB. This innovative approach aims at exploiting the tumor antigen GPC3 for the therapeutic engagement of 4-1BB, a costimulatory receptor on T cells. The product is designed to bolster the immune system's ability to target and destroy cancer cells and is in the early stages of clinical testing.
